Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA synthetic cannabinoids and their primary metabolites in analytical and pharmacological aspects.

Tandem Mass Spectrometry / methods Drug Inverse Agonism Guanosine 5'-O-(3-Thiotriphosphate) Cannabinoids / pharmacology
CB1R binding affinities Main metabolites Polydrug use Synthetic cannabinoids UHPLC-MS/MS

Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
01 07 2023
Historique:
received: 16 12 2022
revised: 02 05 2023
accepted: 07 05 2023
medline: 29 5 2023
pubmed: 15 5 2023
entrez: 14 5 2023
Statut: ppublish

Résumé

Nowadays, more and more new synthetic cannabinoids (SCs) appearing on the illicit market present challenges to analytical, forensic, and toxicology experts. For a better understanding of the physiological effect of SCs, the key issue is studying their metabolomic and psychoactive properties. In this study, our validated targeted reversed phase UHPLC-MS/MS method was used for determination of urinary concentration of 5F-MDMB-PICA, 4F-MDMB-BICA, and their primary metabolites. The liquid-liquid extraction procedure was applied for the enrichment of SCs. The pharmacological characterization of investigated SCs were studied by radioligand competition binding and ligand stimulated [

Identifiants

DOI: 10.1016/j.taap.2023.116548 PMID: 37182749
pubmed: 37182749
pii: S0041-008X(23)00187-4
doi: 10.1016/j.taap.2023.116548
pii:
doi:

Substances chimiques

5F-MDMB-PICA 0
Guanosine 5'-O-(3-Thiotriphosphate) 37589-80-3
Cannabinoids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

116548

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Robert Berkecz reports financial support and equipment, drugs, or supplies were provided by Ministry of Innovation and Technology of Hungary from the National Research. Robert Berkecz reports a relationship with National Research, Development, and Innovation Office-NKFIA that includes: funding grants.

Auteurs

Szabolcs Dvorácskó (S)

Laboratory of Chemical Biology, Institute of Biochemistry, Biological Research Centre, Temesvári krt. 62, Szeged, Hungary; Department of Medical Chemistry, Albert Szent-Györgyi Medical School, University of Szeged, Dóm tér 8, Szeged, Hungary.

Tímea Körmöczi (T)

Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged Somogyi, utca 4., Szeged, Hungary.

Éva Sija (É)

Department of Forensic Medicine, Albert Szent-Györgyi Health Centre, Kossuth Lajos sgt. 40., Szeged, Hungary.

Balázs Bende (B)

Department of Dermatology and Allergology, Albert Szent-Györgyi Health Center, H-6720 Szeged, Korányi fasor 6., Szeged, Hungary.

Roland Weiczner (R)

Department of Forensic Medicine, Albert Szent-Györgyi Health Centre, Kossuth Lajos sgt. 40., Szeged, Hungary.

Tibor Varga (T)

Drug Laboratory Szeged, Drug Investigation Department, Hungarian Institute for Forensic Sciences, Kossuth Lajos sgt. 22-24, Szeged, Hungary.

István Ilisz (I)

Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged Somogyi, utca 4., Szeged, Hungary.

László Institóris (L)

Department of Forensic Medicine, Albert Szent-Györgyi Health Centre, Kossuth Lajos sgt. 40., Szeged, Hungary.

Éva M Kereszty (ÉM)

Department of Forensic Medicine, Albert Szent-Györgyi Health Centre, Kossuth Lajos sgt. 40., Szeged, Hungary.

Csaba Tömböly (C)

Laboratory of Chemical Biology, Institute of Biochemistry, Biological Research Centre, Temesvári krt. 62, Szeged, Hungary.

Róbert Berkecz (R)

Institute of Pharmaceutical Analysis, Faculty of Pharmacy, University of Szeged Somogyi, utca 4., Szeged, Hungary. Electronic address: berkecz.robert@szte.hu.

Articles similaires

A head-to-head comparison of MM/PBSA and MM/GBSA in predicting binding affinities for the CB

Mei Qian Yau, Clarence W Y Liew, Jing Hen Toh et al.
1.00
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics

Motif mapping during chickpea germination reveals a complex sequential activation of different proteolytic activities.

Indrani Bera, Michael O'Sullivan, Caitriona Scaife et al.
1.00
Cicer Germination Proteolysis Seeds Plant Proteins

Uncovering the therapeutic potential of green pea waste in breast cancer: a multi-target approach utilizing LC-MS/MS metabolomics, molecular networking, and network pharmacology.

Asmaa M Khalil, Omar M Sabry, Hesham I El-Askary et al.
1.00
Humans Pisum sativum Breast Neoplasms Tandem Mass Spectrometry Plant Extracts

Comparative analysis of aldosterone and renin assays for primary aldosteronism screening.

Yuki Taki, Takashi Kono, Kyoko Teruyama et al.
1.00
Hyperaldosteronism Humans Renin Aldosterone Middle Aged

Classifications MeSH

questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Spectrométrie de masse › Spectrométrie de masse en tandem › Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Agonisme inverse des médicaments › Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Thionucléotides › Guanosine 5'-O-(3-thiotriphosphate) › Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Cannabinoïdes › Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA...